---

$6.38

+0.1890 ( +3.05% ) 82.4K

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2023-11-22	Sale	-63588119.00	GNI Group Ltd.
2023-11-22	Sale	-170417.00	Wu Charles C
2023-11-01	Sale	-34380.00	Chen Ruoyu
2023-11-01	Sale	-1866.00	Luo Ying
2023-11-01	Sale	-314652.00	Eastling Thomas Wilson
2023-11-01	Sale	-1866.00	Parry Renate
2023-11-01	Sale	-341652.00	USMAN NASSIM
2023-11-01	Sale	-1866.00	Ying Han
2023-11-01	Sale	-1866.00	Carmichael Gordon
2023-10-31	Buy	811.00	GNI Group Ltd.